252 related articles for article (PubMed ID: 23573612)
21. Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer?
Seidman AD
Nat Clin Pract Oncol; 2006 Apr; 3(4):178-9. PubMed ID: 16596138
[No Abstract] [Full Text] [Related]
22. Overcoming resistance against HER2-targeting agents in fifth-line therapy: is there still a place for bevacizumab in HER2+ breast cancer?
Huemer F; Gampenrieder SP; Schlattau A; Greil R
Clin Breast Cancer; 2014 Feb; 14(1):e17-20. PubMed ID: 24246725
[No Abstract] [Full Text] [Related]
23. The problem of ductal carcinoma in situ of the breast.
Fentiman IS
Ann Chir Gynaecol; 1992; 81(4):334-6. PubMed ID: 1336650
[TBL] [Abstract][Full Text] [Related]
24. [Effects and costs of adjuvant chemotherapy for operable lymph node positive breast cancer with HER2/neu overexpression].
Bult P; Tjan-Heijnen VC; van Krieken H
Ned Tijdschr Geneeskd; 2006 Jul; 150(26):1481; author reply 1481-3. PubMed ID: 16875274
[No Abstract] [Full Text] [Related]
25. The surgical management of ductal carcinoma in situ.
Kumar S; Sacchini V
Breast J; 2010; 16 Suppl 1():S49-52. PubMed ID: 21050311
[TBL] [Abstract][Full Text] [Related]
26. Is excision alone adequate treatment for low-risk ductal carcinoma-in-situ of the breast?
Solin LJ
J Clin Oncol; 2006 Mar; 24(7):1017-9. PubMed ID: 16461780
[No Abstract] [Full Text] [Related]
27. Part V. Adjuvant therapies for ductal carcinoma in situ.
Kim JJ
Curr Probl Cancer; 2000; 24(3):163-74. PubMed ID: 10919317
[No Abstract] [Full Text] [Related]
28. Cardiac toxicity monitoring for HER2-positive breast cancer patients undergoing trastuzumab therapy: are we doing enough?
Gujral DM; Lloyd G; Bhattacharyya S
Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):446-7. PubMed ID: 23583229
[No Abstract] [Full Text] [Related]
29. Downregulation of miR-223 Expression Is an Early Event during Mammary Transformation and Confers Resistance to CDK4/6 Inhibitors in Luminal Breast Cancer.
Citron F; Segatto I; Vinciguerra GLR; Musco L; Russo F; Mungo G; D'Andrea S; Mattevi MC; Perin T; Schiappacassi M; Massarut S; Marchini C; Amici A; Vecchione A; Baldassarre G; Belletti B
Cancer Res; 2020 Mar; 80(5):1064-1077. PubMed ID: 31862778
[TBL] [Abstract][Full Text] [Related]
30. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
von Minckwitz G; Darb-Esfahani S; Loibl S; Huober J; Tesch H; Solbach C; Holms F; Eidtmann H; Dietrich K; Just M; Clemens MR; Hanusch C; Schrader I; Henschen S; Hoffmann G; Tiemann K; Diebold K; Untch M; Denkert C
Breast Cancer Res Treat; 2012 Apr; 132(3):863-70. PubMed ID: 21667238
[TBL] [Abstract][Full Text] [Related]
31. [The role of trastuzumab in mammary carcinoma in The Netherlands].
Willemse PH; de Vries EG
Ned Tijdschr Geneeskd; 2006 Apr; 150(14):770-5. PubMed ID: 16649393
[TBL] [Abstract][Full Text] [Related]
32. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
Paik S; Kim C; Wolmark N
N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
[No Abstract] [Full Text] [Related]
33. Primary systemic therapy in HER2-amplified breast cancer: a clinical review.
Khasraw M; Bell R
Expert Rev Anticancer Ther; 2012 Aug; 12(8):1005-13. PubMed ID: 23030220
[TBL] [Abstract][Full Text] [Related]
34. Salvage treatment for local recurrence after breast-conserving surgery and radiation as initial treatment for mammographically detected ductal carcinoma in situ of the breast.
Solin LJ; Fourquet A; Vicini FA; Haffty B; Taylor M; McCormick B; McNeese M; Pierce LJ; Landmann C; Olivotto IA; Borger J; de La Rochefordiere A; Schultz DJ
Cancer; 2001 Mar; 91(6):1090-7. PubMed ID: 11267953
[TBL] [Abstract][Full Text] [Related]
35. Patients with anti-HER2 responsive disease: definition and adjuvant therapies.
Burstein HJ
Breast; 2011 Oct; 20 Suppl 3():S132-4. PubMed ID: 22015280
[TBL] [Abstract][Full Text] [Related]
36. [Adjuvant therapy with trastuzumab (Herceptin) in primary breast cancer].
Huober J; Jackisch C; Untch M; Möbus V; Wallwiener D; Kaufmann M; Minkwitz G
Zentralbl Gynakol; 2006 Feb; 128(1):30-7. PubMed ID: 16450285
[TBL] [Abstract][Full Text] [Related]
37. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
Park K; Han S; Kim HJ; Kim J; Shin E
Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
[TBL] [Abstract][Full Text] [Related]
38. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
39. HER2 evaluation and its impact on breast cancer treatment decisions.
Goddard KA; Weinmann S; Richert-Boe K; Chen C; Bulkley J; Wax C
Public Health Genomics; 2012; 15(1):1-10. PubMed ID: 21540562
[TBL] [Abstract][Full Text] [Related]
40. Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
Yaal-Hahoshen N; Safra T
Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]